RxDoctor Payments DataLook up a doctor →

David Victor, MD

Transplant Hepatology · Houston, TXNPI 1508048919

Payments from drug & device makers

$1,314,893in general payments, 2019–2025

Across 664 payments — averaging $1980.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$361K
  • Intercept Pharmaceuticals, Inc.$326K
  • Madrigal Pharmaceuticals$174K
  • Gilead$167K
  • Siemens Medical Solutions USA, Inc.$67K
  • Intercept Pharma Europe Ltd.$42K
  • plus $179K from 38 others
$13,021in research payments, 2019–2025

Across 5 payments — averaging $2604.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$13K
  • Novo Nordisk AS$121

What the payments were for

  • Consulting fees$39,59016%
  • Speaking & faculty fees$182,53973%
  • Travel & lodging$13,7606%
  • Food & beverage$13,3115%
  • Education$270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,314,893 in reported general payments places this provider in the 85th percentile of 28 transplant hepatology providers in Texas.

See all transplant hepatology providers in Texas

Medicare billing

Part B allowed, 2024
$124,046
Medicare patients
475
Services billed
1,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin222$721,334
EpclusaSofosbuvir/Velpatasvir18$434,059
OcalivaObeticholic Acid32$306,807
RezdiffraResmetirom31$152,090
Ursodiol221$30,973
Entecavir57$15,033
Mycophenolate Mofetil29$6,012
Azathioprine66$3,166
Tacrolimus12$2,930
Budesonide DrBudesonide16$1,901
Lactulose54$1,753
Spironolactone103$1,225
ConstuloseLactulose32$1,170
Pantoprazole Sodium31$472
FenofibrateFenofibrate Nanocrystallized23$399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$253$721,334222 claims
GileadEpclusa$166,786$434,05918 claims
Intercept Pharmaceuticals, Inc.Ocaliva$325,625$306,80732 claims
Madrigal PharmaceuticalsRezdiffra$173,743$152,09031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 28 transplant hepatology providers in Texas.

Other transplant hepatology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →